Published in Nat Protoc on January 01, 2008
Dispersion as an important step in the Candida albicans biofilm developmental cycle. PLoS Pathog (2010) 2.09
Fungal biofilm resistance. Int J Microbiol (2012) 1.73
Surface functionalization by covalent immobilization of an innovative carvacrol derivative to avoid fungal biofilm formation. AMB Express (2015) 1.39
Microtiter susceptibility testing of microbes growing on peg lids: a miniaturized biofilm model for high-throughput screening. Nat Protoc (2010) 1.36
Presence of extracellular DNA in the Candida albicans biofilm matrix and its contribution to biofilms. Mycopathologia (2009) 1.31
Antifungal drug development: challenges, unmet clinical needs, and new approaches. Cold Spring Harb Perspect Med (2014) 1.31
Risk factors and outcomes of candidemia caused by biofilm-forming isolates in a tertiary care hospital. PLoS One (2012) 1.27
The tea catechin epigallocatechin gallate suppresses cariogenic virulence factors of Streptococcus mutans. Antimicrob Agents Chemother (2010) 1.23
Addition of DNase improves the in vitro activity of antifungal drugs against Candida albicans biofilms. Mycoses (2011) 1.18
The transcriptional regulator Nrg1p controls Candida albicans biofilm formation and dispersion. Eukaryot Cell (2010) 1.16
Design of a simple model of Candida albicans biofilms formed under conditions of flow: development, architecture, and drug resistance. Mycopathologia (2009) 1.15
Carbohydrate Derived Fulvic Acid: An in vitro Investigation of a Novel Membrane Active Antiseptic Agent Against Candida albicans Biofilms. Front Microbiol (2012) 1.14
Biofilms formed by Candida albicans bloodstream isolates display phenotypic and transcriptional heterogeneity that are associated with resistance and pathogenicity. BMC Microbiol (2014) 1.14
A 96-well-plate-based optical method for the quantitative and qualitative evaluation of Pseudomonas aeruginosa biofilm formation and its application to susceptibility testing. Nat Protoc (2010) 1.07
Characteristics of Candida albicans biofilms grown in a synthetic urine medium. J Clin Microbiol (2009) 1.05
Candidiasis drug discovery and development: new approaches targeting virulence for discovering and identifying new drugs. Expert Opin Drug Discov (2013) 1.03
Biofilm formation is a risk factor for mortality in patients with Candida albicans bloodstream infection-Scotland, 2012-2013. Clin Microbiol Infect (2015) 1.01
Azole resistance by loss of function of the sterol Δ⁵,⁶-desaturase gene (ERG3) in Candida albicans does not necessarily decrease virulence. Antimicrob Agents Chemother (2012) 1.01
Antifungal therapy with an emphasis on biofilms. Curr Opin Pharmacol (2013) 1.00
Development of a high-throughput Candida albicans biofilm chip. PLoS One (2011) 1.00
In vitro activities of anidulafungin and other antifungal agents against biofilms formed by clinical isolates of different Candida and Aspergillus species. Antimicrob Agents Chemother (2011) 1.00
Extrinsic extracellular DNA leads to biofilm formation and colocalizes with matrix polysaccharides in the human pathogenic fungus Aspergillus fumigatus. Front Microbiol (2013) 0.99
Effects of fluconazole, amphotericin B, and caspofungin on Candida albicans biofilms under conditions of flow and on biofilm dispersion. Antimicrob Agents Chemother (2011) 0.98
High-throughput screening of a collection of known pharmacologically active small compounds for identification of Candida albicans biofilm inhibitors. Antimicrob Agents Chemother (2013) 0.96
Identification, in vitro activity and mode of action of phosphoinositide-dependent-1 kinase inhibitors as antifungal molecules. ACS Chem Biol (2011) 0.94
BRG1 and NRG1 form a novel feedback circuit regulating Candida albicans hypha formation and virulence. Mol Microbiol (2012) 0.92
Antibacterial bisabolane-type sesquiterpenoids from the sponge-derived fungus Aspergillus sp. Mar Drugs (2012) 0.91
Role of sortase in Streptococcus mutans under the effect of nicotine. Int J Oral Sci (2013) 0.91
Candida biofilms and the host: models and new concepts for eradication. Int J Microbiol (2011) 0.89
Bioactive phenylalanine derivatives and cytochalasins from the soft coral-derived fungus, Aspergillus elegans. Mar Drugs (2013) 0.89
(±)-Pestalachloride D, an antibacterial racemate of chlorinated benzophenone derivative from a soft coral-derived fungus Pestalotiopsis sp. Mar Drugs (2013) 0.88
Ochracenoids A and B, guaiazulene-based analogues from gorgonian Anthogorgia ochracea collected from the South China Sea. Mar Drugs (2014) 0.87
A high-throughput assay of yeast cell lysis for drug discovery and genetic analysis. Nat Protoc (2010) 0.87
In vitro study of sequential fluconazole and caspofungin treatment against Candida albicans biofilms. Antimicrob Agents Chemother (2013) 0.86
A murine model for catheter-associated candiduria. J Med Microbiol (2011) 0.86
The Fungal Exopolysaccharide Galactosaminogalactan Mediates Virulence by Enhancing Resistance to Neutrophil Extracellular Traps. PLoS Pathog (2015) 0.86
Overcoming antifungal resistance. Drug Discov Today Technol (2014) 0.85
A Novel Small Molecule Inhibitor of Candida albicans Biofilm Formation, Filamentation and Virulence with Low Potential for the Development of Resistance. NPJ Biofilms Microbiomes (2015) 0.85
Expression of UME6, a key regulator of Candida albicans hyphal development, enhances biofilm formation via Hgc1- and Sun41-dependent mechanisms. Eukaryot Cell (2012) 0.84
An easy and economical in vitro method for the formation of Candida albicans biofilms under continuous conditions of flow. Virulence (2010) 0.84
Susceptibility of Pneumocystis to echinocandins in suspension and biofilm cultures. Antimicrob Agents Chemother (2011) 0.84
Interaction of the echinocandin caspofungin with amphotericin B or voriconazole against Aspergillus biofilms in vitro. Antimicrob Agents Chemother (2012) 0.84
Comparative evolution of morphological regulatory functions in Candida species. Eukaryot Cell (2013) 0.84
Bisbibenzyls, a new type of antifungal agent, inhibit morphogenesis switch and biofilm formation through upregulation of DPP3 in Candida albicans. PLoS One (2011) 0.84
Effect of silver nanoparticles on Candida albicans biofilms: an ultrastructural study. J Nanobiotechnology (2015) 0.84
Effect of tetrandrine against Candida albicans biofilms. PLoS One (2013) 0.84
High-content phenotypic screenings to identify inhibitors of Candida albicans biofilm formation and filamentation. Pathog Dis (2014) 0.82
Extracellular DNA release confers heterogeneity in Candida albicans biofilm formation. BMC Microbiol (2014) 0.82
Species-specific and drug-specific differences in susceptibility of Candida biofilms to echinocandins: characterization of less common bloodstream isolates. Antimicrob Agents Chemother (2013) 0.82
Inhibition of Aspergillus fumigatus and Its Biofilm by Pseudomonas aeruginosa Is Dependent on the Source, Phenotype and Growth Conditions of the Bacterium. PLoS One (2015) 0.82
Anti-biofilm activity of low-molecular weight chitosan hydrogel against Candida species. Med Microbiol Immunol (2013) 0.81
Two new stemphol sulfates from the mangrove endophytic fungus Stemphylium sp. 33231. J Antibiot (Tokyo) (2015) 0.81
Micafungin at physiological serum concentrations shows antifungal activity against Candida albicans and Candida parapsilosis biofilms. Antimicrob Agents Chemother (2014) 0.81
Candida albicans Fungaemia following Traumatic Urethral Catheterisation in a Paraplegic Patient with Diabetes Mellitus and Candiduria Treated by Caspofungin. Case Rep Infect Dis (2013) 0.81
Caspofungin at catheter lock concentrations eradicates mature biofilms of Candida lusitaniae and Candida guilliermondii. Antimicrob Agents Chemother (2014) 0.81
Investigating the biological properties of carbohydrate derived fulvic acid (CHD-FA) as a potential novel therapy for the management of oral biofilm infections. BMC Oral Health (2013) 0.81
Adhesion, biofilm formation, cell surface hydrophobicity, and antifungal planktonic susceptibility: relationship among Candida spp. Front Microbiol (2015) 0.81
In vitro activities of antifungal combinations against biofilms and planktonic forms of clinical Trichosporon asahii isolates. Antimicrob Agents Chemother (2014) 0.80
Candida albicans biofilm chip (CaBChip) for high-throughput antifungal drug screening. J Vis Exp (2012) 0.80
In vitro analysis of finasteride activity against Candida albicans urinary biofilm formation and filamentation. Antimicrob Agents Chemother (2014) 0.80
Activities of fluconazole, caspofungin, anidulafungin, and amphotericin B on planktonic and biofilm Candida species determined by microcalorimetry. Antimicrob Agents Chemother (2014) 0.80
nBioChip, a Lab-on-a-Chip Platform of Mono- and Polymicrobial Biofilms for High-Throughput Downstream Applications. mSphere (2017) 0.79
In vitro interaction between alginate lyase and amphotericin B against Aspergillus fumigatus biofilm determined by different methods. Antimicrob Agents Chemother (2012) 0.79
Berberine Antifungal Activity in Fluconazole-Resistant Pathogenic Yeasts: Action Mechanism Evaluated by Flow Cytometry and Biofilm Growth Inhibition in Candida spp. Antimicrob Agents Chemother (2016) 0.79
In Vitro Activity of Miltefosine against Candida albicans under Planktonic and Biofilm Growth Conditions and In Vivo Efficacy in a Murine Model of Oral Candidiasis. Antimicrob Agents Chemother (2015) 0.78
Biofilm Production and Antibiofilm Activity of Echinocandins and Liposomal Amphotericin B in Echinocandin-Resistant Yeast Species. Antimicrob Agents Chemother (2016) 0.78
Phomopsichin A-D; Four New Chromone Derivatives from Mangrove Endophytic Fungus Phomopsis sp. 33. Mar Drugs (2016) 0.78
Biofilm formation of the black yeast-like fungus Exophiala dermatitidis and its susceptibility to antiinfective agents. Sci Rep (2017) 0.77
Activity of Scorpion Venom-Derived Antifungal Peptides against Planktonic Cells of Candida spp. and Cryptococcus neoformans and Candida albicans Biofilms. Front Microbiol (2016) 0.77
Development of a 96-well catheter-based microdilution method to test antifungal susceptibility of Candida biofilms. J Antimicrob Chemother (2011) 0.77
Effects of Iron Chelators on the Formation and Development of Aspergillus fumigatus Biofilm. Antimicrob Agents Chemother (2015) 0.77
In Vitro Interactions between Non-Steroidal Anti-Inflammatory Drugs and Antifungal Agents against Planktonic and Biofilm Forms of Trichosporon asahii. PLoS One (2016) 0.77
Potent Antifouling Marine Dihydroquinolin-2(1H)-one-Containing Alkaloids from the Gorgonian Coral-Derived Fungus Scopulariopsis sp. Mar Biotechnol (NY) (2015) 0.77
Screening the "Pathogen Box" for the Identification of Candida albicans Biofilm Inhibitors. Antimicrob Agents Chemother (2016) 0.77
Effect of usnic acid on Candida orthopsilosis and C. parapsilosis. Antimicrob Agents Chemother (2011) 0.77
Candida albicans Mycofilms Support Staphylococcus aureus Colonization and Enhances Miconazole Resistance in Dual-Species Interactions. Front Microbiol (2017) 0.77
Evaluation of the Effects of Photodynamic Therapy Alone and Combined with Standard Antifungal Therapy on Planktonic Cells and Biofilms of Fusarium spp. and Exophiala spp. Front Microbiol (2016) 0.76
In vitro analyses of mild heat stress in combination with antifungal agents against Aspergillus fumigatus biofilm. Antimicrob Agents Chemother (2013) 0.76
The Role of Isocitrate Lyase (ICL1) in the Metabolic Adaptation of Candida albicans Biofilms. Jundishapur J Microbiol (2016) 0.76
Micafungin triggers caspase-dependent apoptosis in Candida albicans and Candida parapsilosis biofilms, including caspofungin non-susceptible isolates. Virulence (2015) 0.76
From Biology to Drug Development: New Approaches to Combat the Threat of Fungal Biofilms. Microbiol Spectr (2015) 0.76
Mitochondrial Complex V α Subunit Is Critical for Candida albicans Pathogenicity through Modulating Multiple Virulence Properties. Front Microbiol (2017) 0.75
Inactivation of Candida biofilms by non-thermal plasma and its enhancement for fungistatic effect of antifungal drugs. PLoS One (2012) 0.75
An In Vitro Model for Oral Mixed Biofilms of Candida albicans and Streptococcus gordonii in Synthetic Saliva. Front Microbiol (2016) 0.75
Resistance of Candida albicans Biofilms to Drugs and the Host Immune System. Jundishapur J Microbiol (2016) 0.75
Effectiveness of disinfectants used in hemodialysis against both Candida orthopsilosis and C. parapsilosis sensu stricto biofilms. Antimicrob Agents Chemother (2013) 0.75
Plasticity of Candida albicans Biofilms. Microbiol Mol Biol Rev (2016) 0.75
Investigating the function of Ddr48p in Candida albicans. Eukaryot Cell (2012) 0.75
Characterization of Pleurotus ostreatus biofilms by using the calgary biofilm device. Appl Environ Microbiol (2013) 0.75
Exploring ecological modelling to investigate factors governing the colonization success in nosocomial environment of Candida albicans and other pathogenic yeasts. Sci Rep (2016) 0.75
Antifungal Activity of the Biphosphinic Cyclopalladate C7a against Candida albicans Yeast Forms In Vitro and In Vivo. Front Microbiol (2017) 0.75
The calcineruin inhibitor cyclosporine a synergistically enhances the susceptibility of Candida albicans biofilms to fluconazole by multiple mechanisms. BMC Microbiol (2016) 0.75
The Role of Antifungals against Candida Biofilm in Catheter-Related Candidemia. Antibiotics (Basel) (2014) 0.75
SNF3 as High Affinity Glucose Sensor and Its Function in Supporting the Viability of Candida glabrata under Glucose-Limited Environment. Front Microbiol (2015) 0.75
Repurposing Approach Identifies Auranofin with Broad Spectrum Antifungal Activity That Targets Mia40-Erv1 Pathway. Front Cell Infect Microbiol (2017) 0.75
The Anti-Adhesive Effect of Curcumin on Candida albicans Biofilms on Denture Materials. Front Microbiol (2017) 0.75
The Naturally Occurring Host Defense Peptide, LL-37, and Its Truncated Mimetics KE-18 and KR-12 Have Selected Biocidal and Antibiofilm Activities Against Candida albicans, Staphylococcus aureus, and Escherichia coli In vitro. Front Microbiol (2017) 0.75
In Vitro Interactions of Antifungal Agents and Tacrolimus against Aspergillus Biofilms. Antimicrob Agents Chemother (2015) 0.75
Antifungal activity of Myriocin on clinically relevant Aspergillus fumigatus strains producing biofilm. BMC Microbiol (2015) 0.75
The non-Geldanamycin Hsp90 inhibitors enhanced the antifungal activity of fluconazole. Am J Transl Res (2015) 0.75
Bacterial biofilms: a common cause of persistent infections. Science (1999) 40.82
Biofilms: microbial life on surfaces. Emerg Infect Dis (2002) 7.57
Regulation of cell-surface genes and biofilm formation by the C. albicans transcription factor Bcr1p. Curr Biol (2005) 4.97
Standardized method for in vitro antifungal susceptibility testing of Candida albicans biofilms. Antimicrob Agents Chemother (2001) 4.89
Antifungal susceptibility of Candida biofilms: unique efficacy of amphotericin B lipid formulations and echinocandins. Antimicrob Agents Chemother (2002) 4.52
Candida biofilms: an update. Eukaryot Cell (2005) 3.58
Investigation of multidrug efflux pumps in relation to fluconazole resistance in Candida albicans biofilms. J Antimicrob Chemother (2002) 3.18
Innovative endpoint determination system for antifungal susceptibility testing of yeasts. Antimicrob Agents Chemother (1992) 3.09
Nosocomial fungal infections: epidemiology, diagnosis, and treatment. Med Mycol (2007) 3.02
Biofilm matrix of Candida albicans and Candida tropicalis: chemical composition and role in drug resistance. J Med Microbiol (2006) 2.76
In vitro activity of caspofungin against Candida albicans biofilms. Antimicrob Agents Chemother (2002) 2.67
Candida albicans biofilms: a developmental state associated with specific and stable gene expression patterns. Eukaryot Cell (2004) 2.61
In vitro pharmacodynamic properties of three antifungal agents against preformed Candida albicans biofilms determined by time-kill studies. Antimicrob Agents Chemother (2002) 2.60
Fungal infections: a growing threat. Public Health Rep (1996) 2.59
Effect of growth rate on resistance of Candida albicans biofilms to antifungal agents. Antimicrob Agents Chemother (1998) 2.39
Denture stomatitis: a role for Candida biofilms. Oral Surg Oral Med Oral Pathol Oral Radiol Endod (2004) 2.11
Uses and limitations of the XTT assay in studies of Candida growth and metabolism. J Clin Microbiol (2003) 1.90
Biofilm formation of Candida albicans is variably affected by saliva and dietary sugars. Arch Oral Biol (2004) 1.66
Development of a simple model for studying the effects of antifungal agents on multicellular communities of Aspergillus fumigatus. J Med Microbiol (2007) 1.50
Antifungal combinations against Candida albicans biofilms in vitro. Antimicrob Agents Chemother (2003) 1.45
Recent trends in the epidemiology of invasive mycoses. Curr Opin Infect Dis (2002) 1.43
Susceptibility of Cryptococcus neoformans biofilms to antifungal agents in vitro. Antimicrob Agents Chemother (2006) 1.42
Comparison of three assays for the quantification of Candida biomass in suspension and CDC reactor grown biofilms. J Microbiol Methods (2005) 1.35
Iron-limited biofilms of Candida albicans and their susceptibility to amphotericin B. Antimicrob Agents Chemother (1998) 1.34
The use of new probes and stains for improved assessment of cell viability and extracellular polymeric substances in Candida albicans biofilms. Mycopathologia (2005) 1.26
Integration of Raman microscopy, differential interference contrast microscopy, and attenuated total reflection Fourier transform infrared spectroscopy to investigate chlorhexidine spatial and temporal distribution in Candida albicans biofilms. J Microbiol Methods (2001) 1.13
A seed and feed model for the formation of Candida albicans biofilms under flow conditions using an improved modified Robbins device. Rev Iberoam Micol (2008) 1.09
Interspecies variation in Candida biofilm formation studied using the Calgary biofilm device. APMIS (2006) 1.00
A subpopulation of Candida albicans and Candida tropicalis biofilm cells are highly tolerant to chelating agents. FEMS Microbiol Lett (2007) 0.97
Non-glucan attached proteins of Candida albicans biofilm formed on various surfaces. Mycopathologia (2006) 0.93
Engineered control of cell morphology in vivo reveals distinct roles for yeast and filamentous forms of Candida albicans during infection. Eukaryot Cell (2003) 4.71
In vitro activity of caspofungin against Candida albicans biofilms. Antimicrob Agents Chemother (2002) 2.67
Hsp90 orchestrates temperature-dependent Candida albicans morphogenesis via Ras1-PKA signaling. Curr Biol (2009) 2.50
Dispersion as an important step in the Candida albicans biofilm developmental cycle. PLoS Pathog (2010) 2.09
Calcineurin is essential for Candida albicans survival in serum and virulence. Eukaryot Cell (2003) 1.98
Our current understanding of fungal biofilms. Crit Rev Microbiol (2009) 1.79
Propionibacterium acnes types I and II represent phylogenetically distinct groups. J Clin Microbiol (2005) 1.75
Hsp90 governs dispersion and drug resistance of fungal biofilms. PLoS Pathog (2011) 1.53
Development of a simple model for studying the effects of antifungal agents on multicellular communities of Aspergillus fumigatus. J Med Microbiol (2007) 1.50
Drosophila melanogaster as a facile model for large-scale studies of virulence mechanisms and antifungal drug efficacy in Candida species. J Infect Dis (2006) 1.46
Antifungal combinations against Candida albicans biofilms in vitro. Antimicrob Agents Chemother (2003) 1.45
The calcineurin target, Crz1, functions in azole tolerance but is not required for virulence of Candida albicans. Infect Immun (2004) 1.44
Fluctuations in phenotypes and genotypes within populations of Pseudomonas aeruginosa in the cystic fibrosis lung during pulmonary exacerbations. J Med Microbiol (2009) 1.41
Identification of bacteria on the surface of clinically infected and non-infected prosthetic hip joints removed during revision arthroplasties by 16S rRNA gene sequencing and by microbiological culture. Arthritis Res Ther (2007) 1.40
Pulmonary infection with an interferon-gamma-producing Cryptococcus neoformans strain results in classical macrophage activation and protection. Am J Pathol (2010) 1.36
Identification and molecular characterisation of New Delhi metallo-β-lactamase-1 (NDM-1)- and NDM-6-producing Enterobacteriaceae from New Zealand hospitals. Int J Antimicrob Agents (2012) 1.33
Inhibition of filamentation can be used to treat disseminated candidiasis. Antimicrob Agents Chemother (2006) 1.32
Presence of extracellular DNA in the Candida albicans biofilm matrix and its contribution to biofilms. Mycopathologia (2009) 1.31
Inducible defense mechanism against nitric oxide in Candida albicans. Eukaryot Cell (2004) 1.29
The cdr1B efflux transporter is associated with non-cyp51a-mediated itraconazole resistance in Aspergillus fumigatus. J Antimicrob Chemother (2013) 1.29
CAMP factor homologues in Propionibacterium acnes: a new protein family differentially expressed by types I and II. Microbiology (2005) 1.28
Proteomics for the analysis of the Candida albicans biofilm lifestyle. Proteomics (2006) 1.27
Treatment and prevention of Candida albicans biofilms with caspofungin in a novel central venous catheter murine model of candidiasis. J Antimicrob Chemother (2009) 1.27
Candida albicans-endothelial cell interactions: a key step in the pathogenesis of systemic candidiasis. Infect Immun (2008) 1.26
Role of IL-17A on resolution of pulmonary C. neoformans infection. PLoS One (2011) 1.25
Rapid colorimetric assay for antimicrobial susceptibility testing of Pseudomonas aeruginosa. Antimicrob Agents Chemother (2004) 1.21
Phase-dependent antifungal activity against Aspergillus fumigatus developing multicellular filamentous biofilms. J Antimicrob Chemother (2008) 1.19
Pseudomonas aeruginosa and their small diffusible extracellular molecules inhibit Aspergillus fumigatus biofilm formation. FEMS Microbiol Lett (2010) 1.18
The transcriptional regulator Nrg1p controls Candida albicans biofilm formation and dispersion. Eukaryot Cell (2010) 1.16
Design of a simple model of Candida albicans biofilms formed under conditions of flow: development, architecture, and drug resistance. Mycopathologia (2009) 1.15
Oral candidosis--clinical challenges of a biofilm disease. Crit Rev Microbiol (2011) 1.15
Carbohydrate Derived Fulvic Acid: An in vitro Investigation of a Novel Membrane Active Antiseptic Agent Against Candida albicans Biofilms. Front Microbiol (2012) 1.14
Comparison of biofilm-associated cell survival following in vitro exposure of meticillin-resistant Staphylococcus aureus biofilms to the antibiotics clindamycin, daptomycin, linezolid, tigecycline and vancomycin. Int J Antimicrob Agents (2008) 1.13
Quorum-sensing mutations affect attachment and stability of Burkholderia cenocepacia biofilms. Appl Environ Microbiol (2005) 1.13
Extracellular DNA release acts as an antifungal resistance mechanism in mature Aspergillus fumigatus biofilms. Eukaryot Cell (2013) 1.13
Extensive diversification is a common feature of Pseudomonas aeruginosa populations during respiratory infections in cystic fibrosis. J Cyst Fibros (2013) 1.12
Biofilm formation by Scottish clinical isolates of Staphylococcus aureus. J Med Microbiol (2008) 1.10
Interleukin-17 is not required for classical macrophage activation in a pulmonary mouse model of Cryptococcus neoformans infection. Infect Immun (2010) 1.10
Insights into the mechanisms of protective immunity against Cryptococcus neoformans infection using a mouse model of pulmonary cryptococcosis. PLoS One (2009) 1.10
Use of a genetically engineered strain to evaluate the pathogenic potential of yeast cell and filamentous forms during Candida albicans systemic infection in immunodeficient mice. Infect Immun (2007) 1.09
Characteristics of Candida albicans biofilms grown in a synthetic urine medium. J Clin Microbiol (2009) 1.05
Influence of tigecycline on expression of virulence factors in biofilm-associated cells of methicillin-resistant Staphylococcus aureus. Antimicrob Agents Chemother (2009) 1.04
Candidiasis drug discovery and development: new approaches targeting virulence for discovering and identifying new drugs. Expert Opin Drug Discov (2013) 1.03
Protective immunity against pulmonary cryptococcosis is associated with STAT1-mediated classical macrophage activation. J Immunol (2012) 1.02
Use of artificial sputum medium to test antibiotic efficacy against Pseudomonas aeruginosa in conditions more relevant to the cystic fibrosis lung. J Vis Exp (2012) 1.02
Azole resistance of Aspergillus fumigatus biofilms is partly associated with efflux pump activity. Antimicrob Agents Chemother (2011) 1.01
Development of a high-throughput Candida albicans biofilm chip. PLoS One (2011) 1.00
Antifungal therapy with an emphasis on biofilms. Curr Opin Pharmacol (2013) 1.00
A 96 well microtiter plate-based method for monitoring formation and antifungal susceptibility testing of Candida albicans biofilms. J Vis Exp (2010) 0.98
Effects of fluconazole, amphotericin B, and caspofungin on Candida albicans biofilms under conditions of flow and on biofilm dispersion. Antimicrob Agents Chemother (2011) 0.98
Protective immunity against experimental pulmonary cryptococcosis in T cell-depleted mice. Clin Vaccine Immunol (2011) 0.98
Reducing the incidence of denture stomatitis: are denture cleansers sufficient? J Prosthodont (2010) 0.97
The characteristics of Aspergillus fumigatus mycetoma development: is this a biofilm? Med Mycol (2008) 0.97
Adhesion of Candida albicans to endothelial cells under physiological conditions of flow. Infect Immun (2009) 0.97
Depletion of neutrophils in a protective model of pulmonary cryptococcosis results in increased IL-17A production by γδ T cells. BMC Immunol (2012) 0.96
Development of a multiplex and real time PCR assay for the specific detection of Arcobacter butzleri and Arcobacter cryaerophilus. J Microbiol Methods (2006) 0.95
High-throughput nano-biofilm microarray for antifungal drug discovery. MBio (2013) 0.94
Antifungal treatment affects the laboratory diagnosis of invasive aspergillosis. J Clin Pathol (2011) 0.93
Effect of antibiotic treatment on bacteriophage production by a cystic fibrosis epidemic strain of Pseudomonas aeruginosa. Antimicrob Agents Chemother (2010) 0.93
Candida albicans biofilm formation and its clinical consequences. Future Microbiol (2009) 0.93
Candida-specific antibodies during experimental vaginal candidiasis in mice. Infect Immun (2002) 0.90
Efflux pumps may play a role in tigecycline resistance in Burkholderia species. Int J Antimicrob Agents (2010) 0.90
Efficacy of a genetically engineered Candida albicans tet-NRG1 strain as an experimental live attenuated vaccine against hematogenously disseminated candidiasis. Clin Vaccine Immunol (2009) 0.89
Mechanisms of dendritic cell lysosomal killing of Cryptococcus. Sci Rep (2012) 0.89
A proteomic-based approach for the identification of immunodominant Cryptococcus neoformans proteins. Proteomics (2009) 0.89
Some biological features of Candida albicans mutants for genes coding fungal proteins containing the CFEM domain. FEMS Yeast Res (2011) 0.87
Induction of protective immunity against cryptococcosis. Mycopathologia (2011) 0.87
In vitro study of sequential fluconazole and caspofungin treatment against Candida albicans biofilms. Antimicrob Agents Chemother (2013) 0.86
Vaccine and immunotherapeutic approaches for the prevention of cryptococcosis: lessons learned from animal models. Front Microbiol (2012) 0.86
Improved early diagnosis of Pseudomonas aeruginosa by real-time PCR to prevent chronic colonisation in a paediatric cystic fibrosis population. J Cyst Fibros (2011) 0.86
Activity of pyocin S2 against Pseudomonas aeruginosa biofilms. Antimicrob Agents Chemother (2011) 0.86
Overcoming antifungal resistance. Drug Discov Today Technol (2014) 0.85
Identification and characterization of Cryptococcus neoformans protein fractions that induce protective immune responses. Proteomics (2013) 0.85
Hydrolytic enzyme production is associated with Candida albicans biofilm formation from patients with type 1 diabetes. Mycopathologia (2010) 0.84
Candida albicans: adapting to succeed. Cell Host Microbe (2013) 0.84
An easy and economical in vitro method for the formation of Candida albicans biofilms under continuous conditions of flow. Virulence (2010) 0.84
Expression of UME6, a key regulator of Candida albicans hyphal development, enhances biofilm formation via Hgc1- and Sun41-dependent mechanisms. Eukaryot Cell (2012) 0.84
Attachment of Candida albicans to denture base acrylic resin processed by three different methods. Int J Prosthodont (2010) 0.84
Commercial mouthwashes are ineffective against oral MRSA biofilms. Oral Surg Oral Med Oral Pathol Oral Radiol (2013) 0.82
Proteomics to study Candida albicans biology and pathogenicity. Infect Disord Drug Targets (2006) 0.82
Cryptococcus antigens and immune responses: implications for a vaccine. Expert Rev Vaccines (2013) 0.82
Molecular detection of transcriptionally active bacteria from failed prosthetic hip joints removed during revision arthroplasty. Eur J Clin Microbiol Infect Dis (2010) 0.82
High-content phenotypic screenings to identify inhibitors of Candida albicans biofilm formation and filamentation. Pathog Dis (2014) 0.82
Candida albicans Fungaemia following Traumatic Urethral Catheterisation in a Paraplegic Patient with Diabetes Mellitus and Candiduria Treated by Caspofungin. Case Rep Infect Dis (2013) 0.81
Investigating the biological properties of carbohydrate derived fulvic acid (CHD-FA) as a potential novel therapy for the management of oral biofilm infections. BMC Oral Health (2013) 0.81
Recent advances on filamentous fungal biofilms for industrial uses. Appl Biochem Biotechnol (2012) 0.81
High osmolarity glycerol response PtcB phosphatase is important for Aspergillus fumigatus virulence. Mol Microbiol (2015) 0.81
Clinical associations between IL-17 family cytokines and periodontitis and potential differential roles for IL-17A and IL-17E in periodontal immunity. Inflamm Res (2014) 0.80
Candida albicans biofilm chip (CaBChip) for high-throughput antifungal drug screening. J Vis Exp (2012) 0.80
Respiratory tract infections and pneumonia. Periodontol 2000 (2009) 0.80
Fungal biofilms in human disease. Adv Exp Med Biol (2015) 0.80
Immunology of fungal infections: lessons learned from animal models. Curr Opin Microbiol (2012) 0.79
Identifying the bacterial community on the surface of Intralox belting in a meat boning room by culture-dependent and culture-independent 16S rDNA sequence analysis. Int J Food Microbiol (2006) 0.79